XORTX Therapeutics Inc. Common Stock
XRTXStock
$2.11−67.95%52W
Market Cap$5.07M
P/E—
Div yield—
Beta0.03
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-53.54%
Price vs S&P 500 (4W)7.28%
VGM Score56.81
Market Capitalization$5.07M
Analyst Recommendations
Dec 2023
Jan 2024
Feb 2024
Mar 2024
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
XRTXXORTX Therapeutics Inc. Common Stock | B | — | D | $2.11 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
XORTX Therapeutics is a clinical-stage biotechnology company developing therapies for progressive kidney disease by targeting purine and uric acid metabolism. The company is advancing three therapeutic candidates for rare kidney disease indications including ADPKD and Type 2 Diabetic Nephropathy, as well as acute kidney injury associated with respiratory infections. The company aims to slow or reverse chronic kidney disease progression and explore additional indications leveraging its intellectual property.